Abstract: Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFR? and/or PDGFR? kinase activity.

Abstract: A culture medium for hepatoma organoid culture, comprising an MST1/2 kinase inhibitor, at least one cell culture additive selected from N2 and B27, a hepatocyte growth factor, an ITS cell culture additive, Y27632, dexamethasone, Neuregulin-1, insulin, an epidermal cell growth factor, GlutaMAX, and non-essential amino acids. The application further relates to a hepatoma organoid culture method and an application thereof. By using the culture medium for hepatoma organoid, effective and rapid expansion of the hepatoma organoid can be achieved, and the organoid obtained by such expansion maintains the pathological characteristics of a patient, improves the culture success rate and the expansion rate of the hepatoma organoid, and provides a research basis for individualized treatment of the patient.

Abstract: A culture medium for culturing mammary epithelial cells, which medium contains ?-estradiol, insulin-like growth factor 1, basic fibroblast growth factor, tumor necrosis factor-?, and optionally fibroblast growth factor 10. A method for culturing mammary epithelial cells using the culture medium, and a method and the use of cells obtained using the culture method in evaluating or screening the efficacy of a drug.

Abstract: Provided are a culture medium and a culture method for human primary acute myeloid leukemia cells. The culture medium for human primary acute myeloid leukemia cells contains a glutamine additive, non-essential amino acids, human interleukin-6, human interleukin-7, human interleukin-3, recombinant human FLT3 Ligand, a recombinant human macrophage colony stimulating factor and a human stem cell factor. Acute myeloid leukemia cells can be cultured with higher amplification efficiency and longer in-vitro culture time by using the culture medium and culture method. Also provided are human primary acute myeloid leukemia cells cultured in vitro by using the culture medium, and the use thereof for curative effect evaluation and screening of drugs.

Abstract: The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.

Abstract: Provide are a primay cell culture medium that contains an MST1/2 kinase inhibitor and is used for culturing laryngeal cancer epithelial cells, and a culture method using the primary cell culture medium. In the culture method, the primay cell culture medium is used to culture primary cells on a clulture vessel plated with irradiated trophoblasts, so that the primay cells proliferate rapidly. A cell model obtained by the primary cell culture medium and the primay cell culture method can be used for the efficacy evaluation and screening of drugs.

Abstract: Provided is a novel PDGFR kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. Further provided are use and a method of the compound of formula (I) for preventing or treating conditions associated with PDGFR kinase activity, particularly use and a method for preventing or treating conditions associated with PDGFR? and/or PDGFR? kinase activity.

Abstract: The present invention provides a novel pan-RAF kinase inhibitor, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a use or method of the compound of formula (I) in the treatment or prevention of a disorder related to the activity of RAF and/or RAS kinase.